Ad26.COV2.S vaccine

GPTKB entity

Statements (52)
Predicate Object
gptkbp:instanceOf vaccine
viral vector vaccine
gptkbp:activeIngredient recombinant, replication-incompetent adenovirus type 26 vector encoding SARS-CoV-2 spike protein
gptkbp:administeredBy gptkb:Brazil
gptkb:Canada
gptkb:European_Union
gptkb:South_Africa
gptkb:United_States
adults 18 years and older
gptkbp:approvedBy 2021-02-27
gptkbp:ATCCode gptkb:J07BX03
gptkbp:boosterAuthorization gptkb:United_States
gptkbp:boosterAuthorizationDate 2021-10-20
gptkbp:clinicalTrialPhase gptkb:ENSEMBLE_trial
gptkbp:containsAdjuvant no
gptkbp:countryOfOrigin gptkb:United_States
gptkbp:developedBy gptkb:Johnson_&_Johnson
gptkb:Janssen_Pharmaceuticals
gptkbp:dosingRegimen single dose
gptkbp:efficacyAgainstModerateToSevereCOVID19 66%
gptkbp:efficacyAgainstSevereCOVID19 85%
gptkbp:emergencyServices gptkb:European_Union
gptkb:United_States
gptkb:World_Health_Organization
https://www.w3.org/2000/01/rdf-schema#label Ad26.COV2.S vaccine
gptkbp:includedInCOVAX yes
gptkbp:legalStatus gptkb:emergency_use_authorization
conditional marketing authorization
withdrawn in the United States (2023)
gptkbp:marketedAs gptkb:Johnson_&_Johnson_COVID-19_Vaccine
gptkb:Janssen_COVID-19_Vaccine
gptkbp:notRecommendedFor children under 18
people with history of severe allergic reaction to any component
gptkbp:platform adenovirus vector
gptkbp:regulatorySuspension United States (April 2021, temporary)
gptkbp:regulatorySuspensionReason rare blood clot events
gptkbp:routeOfAdministration intramuscular injection
gptkbp:shelfLife up to 3 months at 2–8°C
up to 2 years at -20°C
gptkbp:sideEffect gptkb:Guillain-Barré_syndrome
fever
fatigue
headache
muscle pain
pain at injection site
thrombosis with thrombocytopenia syndrome
gptkbp:storage 2–8°C
gptkbp:target gptkb:COVID-19
gptkbp:UNII Q1Y1J9J8B7
gptkbp:WHOEmergencyUseListing 2021-03-12
gptkbp:bfsParent gptkb:ENSEMBLE_trial
gptkbp:bfsLayer 7